Skip to main content
PMC home page
BMC Cancer logoLink to BMC Cancer
. 2024 Nov 21;24:1436. doi: 10.1186/s12885-024-13210-9

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Armando Santoro 1,2,✉, Garrido Pilar 3, Daniel SW Tan 4, Jon Zugazagoitia 5, Frances A Shepherd 6, Alessandra Bearz 7, Fabrice Barlesi 8,9,10, Tae Min Kim 11, Tobias R Overbeck 12, Enriqueta Felip 13, Can Cai 14, Simantini Eddy 14, Tracey McCulloch 15, Eric S Schaefer 16
PMCID: PMC11580551  PMID: 39574037

Correction : BMC Cancer 24, 1307 (2024)

https://doi.org/10.1186/s12885-024-12841-2

Following publication of the original article [1], the authors identified an error in the author name of Simantini Eddy. Their given name and family name were erroneously transposed.

The incorrect author name is: Eddy Simantini

The correct author name is: Simantini Eddy

The author group has been updated above and the original article [1] has been corrected.

Reference

  • 1.Santoro A, Pilar G, Tan DS, et al. Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC. BMC Cancer. 2024;24:1307. 10.1186/s12885-024-12841-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES